Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease Module - Wikidata - awgldk - TriplyDB

Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease Module

Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease Module

http://www.wikidata.org/entity/Q33791528

about

Mast cell-neural interactions contribute to pain and itch.HABIT, a Randomized Feasibility Trial to Increase Hydroxyurea Adherence, Suggests Improved Health-Related Quality of Life in Youths with Sickle Cell Disease.

P2860

Q50068940-A8D9C85D-A864-41BD-BB14-F270A07EB468 Q52639727-7B7C94A7-CE9E-4095-9FC7-EA2818C91008

P2860

Determining the longitudinal validity and meaningful differences in HRQL of the PedsQL™ Sickle Cell Disease Module

http://www.wikidata.org/entity/Q33791528

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

Determining the longitudinal v ...... QL™ Sickle Cell Disease Module

@ast

Determining the longitudinal v ...... QL™ Sickle Cell Disease Module

@en

type

label

Determining the longitudinal v ...... QL™ Sickle Cell Disease Module

@ast

Determining the longitudinal v ...... QL™ Sickle Cell Disease Module

@en

prefLabel

Determining the longitudinal v ...... QL™ Sickle Cell Disease Module

@ast

Determining the longitudinal v ...... QL™ Sickle Cell Disease Module

@en

P1433

Q33791528-57550081-A702-49E7-A5A6-E2189A13572D

P1476

Q33791528-577689A2-D33F-4E26-906D-625C94940BAA

P2093

Q33791528-1A2EF2EE-048C-4D1E-A3F4-6E524297ACB2

Q33791528-2AC08AED-56CA-4FE3-B155-A1E3C8D42EEB

Q33791528-2BC113FE-112F-45CC-9E06-B3E321529A1D

Q33791528-339A48BD-EB51-48CF-AD93-F61D890965F5

Q33791528-3FB6D928-2A86-423B-8953-6D4826AA35B8

Q33791528-5EB9C89A-252C-418C-ADEC-C423E07E4820

Q33791528-6458C696-2F61-4F9D-8767-22B0529C4DEA

Q33791528-7210CD0B-4D91-41B1-B7F3-C03151EE75B2

Q33791528-8C43D58E-B9E9-44C8-A1D3-E61C897F8757

Q33791528-A500D547-88D7-42B5-BBA0-68308F030A10

P2860

Q33791528-1777C926-3EC2-4A7C-9D4F-26C3DD0977A9

Q33791528-1F5FF293-784A-4822-A751-EE5CA4EAC8A7

Q33791528-21BE2500-D9C7-4791-A644-AD676ADF0D7C

Q33791528-22909C19-1346-44A8-9C15-606F6E21B622

Q33791528-2DA089EB-0151-47D2-A0A4-D2FF8E6E1BD7

Q33791528-2F520445-529E-4187-A5E6-06B983D1A4CC

Q33791528-40E4D336-523A-45A3-AED3-BAB5EC5BD4CA

Q33791528-446A7E3A-2C62-4552-B492-A991E7448F9A

Q33791528-5116FE10-9202-47C1-A078-E96A982DE43F

Q33791528-6FD40616-FEF0-4442-8D4E-BD1CCAE2B61C

P2888

Q33791528-601E1CE3-5091-4367-8D66-60501C1A72A3

P304

Q33791528-E2923D24-780C-46D2-963A-B9F8C3102449

P31

Q33791528-4C00DDF7-4226-48D4-AE64-04BBDEE31FE2

P356

Q33791528-248BED9F-EE98-447A-9EAA-4EA24652554F

P433

Q33791528-A4197519-68E5-479F-9B90-D703C15C4CF5

P478

Q33791528-32A723D0-1AD7-42CE-A208-615661E601C6

P50

Q33791528-5C3C14CC-A83A-45FF-B51B-065218752F5C

Q33791528-BB940F9C-3E89-4A54-9891-173D1CE55EE2

Q33791528-C21F083A-8BDF-4EEB-9F4A-6C2C6EA08FB9

P577

Q33791528-E270B691-2D5D-414F-AFBA-524068090FDC

P6179

Q33791528-4B3C93E2-77ED-40B9-A08B-BFF676DEEE07

P698

Q33791528-C45443FE-3B6F-457E-94E1-0814B9DB618F

P921

Q33791528-03A07E4D-285F-4570-A193-23E33A9F115D

P932

Q33791528-68125688-94C4-4317-80A4-09CEDDB943F9

P356

S12955-017-0700-2

P1433

Health and Quality of Life Outcomes

P1476

Determining the longitudinal v ...... QL™ Sickle Cell Disease Module

@en

P2093

Angela M Ellison

http://www.w3.org/2001/XMLSchema#string

Cheryl A Hillery

http://www.w3.org/2001/XMLSchema#string

David C Brousseau

http://www.w3.org/2001/XMLSchema#string

Elizabeth C Powell

http://www.w3.org/2001/XMLSchema#string

Gladstone E Airewele

http://www.w3.org/2001/XMLSchema#string

J Paul Scott

http://www.w3.org/2001/XMLSchema#string

Julie A Panepinto

http://www.w3.org/2001/XMLSchema#string

Kim Smith-Whitley

http://www.w3.org/2001/XMLSchema#string

Lakshmanan Krishnamurti

http://www.w3.org/2001/XMLSchema#string

Larry J Cook

http://www.w3.org/2001/XMLSchema#string

P2860

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

Impact of family income and sickle cell disease on the health-related quality of life of children.

Linking clinical relevance and statistical significance in evaluating intra-individual changes in health-related quality of life.

Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes.

Responsiveness and minimal important differences for patient reported outcomes.

PedsQL™ sickle cell disease module: feasibility, reliability, and validity.

A multicenter randomized controlled trial of intravenous magnesium for sickle cell pain crisis in children.

Intravenous magnesium for pediatric sickle cell vaso-occlusive crisis: methodological issues of a randomized controlled trial.

A point of minimal important difference (MID): a critique of terminology and methods.

Health-related quality of life in sickle cell disease: past, present, and future.

P2888

s12955-017-0700-2

P304

124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S12955-017-0700-2

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P50

Corrie E Chumpitazi

Deepika Darbari

P577

2017-06-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1085982861

http://www.w3.org/2001/XMLSchema#string

P698

28606098

http://www.w3.org/2001/XMLSchema#string

P921

sickle-cell disease

P932

5468970

http://www.w3.org/2001/XMLSchema#string